Introduction
As multi-group research on an international basis evolved toward the goal of antagonists of the luteinizing hormone releasing hormone (LHRH) for the control of evolution, it has now become compelling that such an antagonist must have adequate potency and preferably release less than or at best no more histamine than that of the superagonists of LHRH which are in clinical use. Although any significant side effect must be absent, the aspect of histamine release has become prominent.
Schmidt et al. [1] observed that the antagonist, [Ac-D-2-Nal 1 , 4FDPhe 2 , D-Trp 3 , D-Trp 6 ]GnRH caused a transient edema of the face and extremities when it was subcutaneously administered to rats.
Karten and Rivier [2] provided a comprehensive account of the design of GnRH analogs, summarized rationale, perspective and structure-function studies, and emphasized the antagonist-induced histamine release of timely importance. They observed that those antagonists of LHRH which were potent in causing histamine release had a basic D-amino acid in position 6 and Arg 8 as well as hydrophobic aromatic * Reprint requests to Dr. Karl Folkers.
Verlag der Zeitschrift für Naturforschung. D-7400 Tübingen 0340 -5087/87/0100 -0101/$ 01.00/0 amino acids in the N-terminus. Other peptides have also been observed to release histamine including somatostatin analogs [3] , neuropeptides [4] , compound 48/80 and substance P, which induced release of histamine and serotonin [5] , and gastrin, which induced release of histamine from human cutaneous mast cells [6] , Progress has been reported on the achievement of designs of antagonists of LHRH which maintain potency of antiovulatory activity (AOA) and minimize histamine release. Folkers et al. [7] Prior to the emphasis on, but not in disregard, of histamine release, significant progress on the design of improved antagonists of LHRH was recently reported. Nestor et al. [9, 10] reported on heteroaromatic and very hydrophobic amino acids. Ho et al. [11] examined azaglycine analogs. Hocart et al. [12] modified position 7 of antagonists. Rivier et al. [13] and Korkhov et al. [13] studied cyclic analogs. Kopple et al. [14] found that NMR data on LHRH antagonists did not indicate a preferred conformation. Millar et al. [15] studied gonadotropin release by a non-GnRH sequence of the GnRH precursor. Sundaram et al. [16] observed species differences in the effects of an antagonist.
We describe herein the design, synthesis, and bioassay data on the potency of AOA and on histamine release for two groups of peptides with emphasis on positions 1, 5 and 6 and on 1, 2 and 3 for a total of 40 peptides.
Experimental

Intermediates
The acquisition of available amino acid intermediates, resin, solvents, and other chemicals has been described [7, 17] D,L-6-Quinolylalanine was prepared from condensation of 6-quinoline carboxylic acid chloride and hippuric acid (C 6 H,CONHCH 2 CO : H) [20] and followed by an acid hydrolysis. The amino acid was then protected with Boc before coupling to peptides, m.p. 231 °C (dec.).
Synthesis
The 40 peptides were synthesized by the automated solid-phase procedure as described [7] ,
Purification and purity
The peptides were purified first by chromatography over silica gel, and then by HPLC using the solvent systems as described [7] . Single peaks were achieved on analytical «-Bondapak Q 8 columns (3.9mm x 30 cm) using phosphate-acetonitrile buffer systems at various concentrations of acetonitrile as recorded in Table III . The chromatographic data are in Table III . The amino acid analytical data of Table IV were obtained as described [7] ,
Biological assay
The bioassays in rats to determine the activities to inhibit ovulation were conducted as described [7] , and the data are in Table I and II. The assay used to determine the release of histamine by these peptides was described by Hook et al. [18] , and the data are in Table I . This system is based on mast cells from adult male Sprague-Dawley rats. In this system, 575 /<g/ml of LHRH released 50% of the total histamine.
Results and Discussion
Activity for inhibition of ovulation
Emphasis on positions 1, 5 and 6: The data in Table I The most potent antagonist of the 17 analogs in Table I is The D-His 6 -analog 6 and the D-7-AzaTrp 6 -analog 7 had equivalent activities of 25% AOA/O.5 jug.
The introduction of D-MeLys in positions 3 and 6 lowered activity to 22% AOA/l.O/zg (analog 7). Analogs 8,9 and 10 which maintain N-Ac-D-2-Nal 1 , but have diverse substitutions in positions 3, 5 and particularly in 6 were of relatively low activity since they showed 11-22% AOA/l.O^g.
Analogs 11 -17 which maintained N-Ac-D-2-Nal 1 , D-3-Pal 3 but had substitutions in positions 5 and 6 showed 0% AOA at the arbitrary levels tested which ranged from 0.25-1.0,ug.
Analogs with emphasis on positions 1, 2 and 3: The 23 analogs in Table II maintained With the exception of analogs 10,12,21 and 23, the remaining analogs 9, 11, 13, 14, 15, 17, 18, 19, 20 and 22 showed some AOA at a dosage of 1.0 /ug which ranged from 10 to 60%.
In perspective, N-terminal acetyl and propionyl are probably about equivalent. D-2-Nal 1 was generally more effective than D-Phe and halogenated Phe's. D-3-Pal 3 was more effective than substituted Lys ? and Trp 3 .
Activity for release of histamine
The most potent analog for AOA was analog 1 of Table I which showed a substantial release of histamine, 184±35 mm/10 ftg. The other analogs of Table I which were assayed in rats for release of histamine showed wheal areas as high as 140±7 mm, and the analog causing this level of histamine release, number 14, had D-His 6 rather than D-Arg 6 . The histamine release level was substantially low for the D-NicLys 6 analog (number 3), 85 mm/10 ug, which was less than half of the amount caused by analog 1. This D-NicLys 6 analog produced 100% inhibition of ovulation at 1 jug. For some analogs, the reduced release of histamine could be associated with reduced potencies for AOA. 
